From: Vision loss in patients with giant cell arteritis treated with tocilizumab
All | |
---|---|
n (%) or median (IQ range) | |
Total N | N = 186 |
Female | 116 (62%) |
Age at diagnosis | 71.0 (63.0; 77.0) |
Weight [kg] | 70.0 (59.0; 83.4) |
BMI [kg/m2] | 24.9 (22.0; 28.4) |
CRP (mg/L) | 50.0 (20.0; 99.0) |
ESR (mm/h) | 70.0 (40.0; 86.3) |
ACR Criteria 1990 | 109 (59%) |
Cranial symptoms (including visual symptoms) | 124 (67%) |
Visual symptoms | 70 (38%) |
Vision loss | 21 (11%) |
Headache | 93 (50%) |
Jaw claudication | 48 (26%) |
Scalp tenderness | 42 (23%) |
Claudication of tongue | 2 (1%) |
Fever ≥ 38 °C | 35 (19%) |
Weight loss > 2 kg within 4 weeks | 50 (27%) |
Night sweat | 33 (18%) |
Polymyalgia rheumatica | 90 (48%) |
Biopsy of the temporal artery performed/positive* | 135 (73%)/73 (54%) |
MR angiography of aorta performed/positive* | 170 (91%)/123 (72%) |
MR angiography of extracranial arties performed/positive* | 132 (71%)/63 (48%) |
PET imaging performed/positive* | 20 (11%)/12 (60%) |
Duplex ultrasound of extracranial arteries performed/positive* | 43 (23%)/18 (42%) |